Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans
Authors:
- 19 June 2006
- journal article
- research article
- Published by Wiley in The FEBS Journal
- Vol. 273 (14) , 3183-3191
Abstract
Candida albicans is the most prevalent yeast pathogen in humans, and recently it has become increasingly resistant to the current antifungal agents. In this study we investigated C. albicans dihydroorotate dehydrogenase (DHODH, EC 1.3.99.11), which catalyzes the fourth step of de novo pyrimidine synthesis, as a new target for controlling infection. We propose that the enzyme is a member of the DHODH family 2, which comprises mitochondrially bound enzymes, with quinone as the direct electron acceptor and oxygen as the final electron acceptor. Full‐length DHODH and N‐terminally truncated DHODH, which lacks the targeting sequence and the transmembrane domain, were subcloned from C. albicans, recombinantly expressed in Escherichia coli, purified, and characterized for their kinetics and substrate specificity. An inhibitor screening with 28 selected compounds was performed. Only the dianisidine derivative, redoxal, and the biphenyl quinoline‐carboxylic acid derivative, brequinar sodium, which are known to be potent inhibitors of mammalian DHODH, markedly reduced C. albicans DHODH activity. This study provides a background for the development of antipyrimidines with high efficacy for decreasing in situ pyrimidine nucleotide pools in C. albicans.Keywords
This publication has 37 references indexed in Scilit:
- Pyrimidine pathways in health and diseaseTrends in Molecular Medicine, 2005
- Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicansAntimicrobial Agents and Chemotherapy, 2004
- Candida morphogenesis and host–pathogen interactionsCurrent Opinion in Microbiology, 2004
- Multidrug Resistance in Yeast Candida2004
- Antifungal Drug ResistanceClinical Infectious Diseases, 2003
- Inhibitors of de Novo Nucleotide Biosynthesis as DrugsAccounts of Chemical Research, 2002
- Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequencesThe Lancet Infectious Diseases, 2002
- Evolutionary implications of the mosaic pyrimidine-biosynthetic pathway in eukaryotesGene, 2000
- Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivativesBiochemical Pharmacology, 1998
- Pyrimidine Nucleotide Biosynthesis in Animals: Genes, Enzymes, and Regulation of UMP BiosynthesisAnnual Review of Biochemistry, 1980